MGB Biopharma Announces Successful Outcome from Phase II Clinical Study with MGB-BP-3 – a Potential New Gold Standard, First-Line Treatment for Clostridium difficile Infection (CDI)
Scottish Biopharmaceutical Company MGB Biopharma Receives £2.78m Grant Award For Phase IIa Clinical Trial
MGB Biopharma Granted Qualified Infectious Disease Product (QIPD) and Fast Track Designation by U.S. FDA for the Treatment of Clostridium difficile-associated Diarrhoea (CDAD) for Tablet Presentation of MGB-BP-3
MGB Biopharma – FDA and Health Canada Clear IND/CTA Applications for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)
